抗NMDA受体脑炎和精神分裂症相关性研究进展
|
摘要
精神分裂症病因未完全明确,N-甲基-D-天冬氨酸(N-methyl-D-aspartic acid receptor,NMDA)受体功能不足是精神分裂症的重要发病机制,随着抗NMDA受体脑炎的发现,以及在精神分裂症人群中也发现抗NMDA受体抗体阳性患者,抗NMDA受体抗体阳性可能是精神分裂症某一种亚型。本文旨在总结抗NMDA受体脑炎及精神分裂症之间相关性的研究结果,进一步拓展对精神分裂症的认识、治疗及评估。
The etiology of schizophrenia is not completely clear. The lack of N-methyl-D-aspartic acid receptor(NMDA) function is an important pathogenesis of schizophrenia. With the discovery of anti-NMDA receptor encephalitis, as well as anti-NMDA receptor antibody-positive patients in schizophrenia, anti-NMDA receptor antibody positive may be a subtype of schizophrenia. This article aims to summarize the findings of the association between anti-NMDA receptor encephalitis and schizophrenia, and further expand our understanding, treatment and evaluation of schizophrenia.
The etiology of schizophrenia is not completely clear. The lack of N-methyl-D-aspartic acid receptor(NMDA) function is an important pathogenesis of schizophrenia. With the discovery of anti-NMDA receptor encephalitis, as well as anti-NMDA receptor antibody-positive patients in schizophrenia, anti-NMDA receptor antibody positive may be a subtype of schizophrenia. This article aims to summarize the findings of the association between anti-NMDA receptor encephalitis and schizophrenia, and further expand our understanding, treatment and evaluation of schizophrenia.
引文
[1]Muller N.Immunology of schizophrenia[J].Neuroimmunomodulation,2014,21(2-3):109-111.
[2]Wang AK,Miller BJ.Meta-analysis of Cerebrospinal Fluid Cytokine and Tryptophan Catabolite Alterations in Psychiatric Patients:Comparisons Between Schizophrenia,Bipolar Disorder,and Depression[J].Schizophr Bull,2018,44(1):75-83.
[3]Pollak TA,McCormackb R,Peakman M,et al.Prevalence of anti-N-methyl-D-aspartate(NMDA)receptor antibodies in patients with schizophrenia and related psychoses:a systematic review and meta-analysis[J].Psychol Med,2014,44(12):2475-2487.
[4]Benros ME,Pedersen MG,Rasmussen H,et al.A nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis[J].Am J Psychiatry,2014,171(2):218-226.
[5]Moghaddam B,Javitt D.From revolution to evolution:the glutamate hypothesis of schizophrenia and its implication for treatment[J].Neuropsychopharmacology,2012,37:4-15.
[6]Dalmau J,Tüzün E,Wu HY,et al.Paraneoplastic antiN-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma[J].Ann Neurol,2007,61(1):25-36.
[7]Titulaer MJ,McCracken L,Gabilondo I,et al.Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis:An observational cohort study[J].Lancet Neurol,2013,12(2):157-165.
[8]刘美云,谢琰臣,李继梅.抗NMDA受体脑炎[J].中国神经免疫学和神经病学杂志,2010,17(6):449-451.
[9]Hughes EG,Peng X,Gleichman AJ,et al.Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis[J].J Neurosci,2010,30:5866-5875.
[10]Forray C,Buller R.Challenges and opportunities for the development of new antipsychotic drugs[J].Biochem Pharmacol,2017,143:10-24.
[11]Krystal JH,Karper LP,Seibyl JP,et al.Subanesthetic effects of the noncompetitive NMDA antagonis ketamine in humans:psychotomimetic,perceptual,cognitive,and neuroendocrine responses[J].Arch Gen Psychiatry,1994,51:199-214.
[12]陈小红,周凤,刘兴媛,等.抗NMDA受体脑炎患者1例报道及文献学习[J].中国实用神经疾病杂志,2018(8):905-908.
[13]Javitt DC,Zukin SR.Recent advances in the phencyclidine model of schizophrenia[J].Am J Psychiatry,1991,148:1301-1308.
[14]Kiowa C,DeGiorgio LA,Nakaoka T,et al.Cognition and immunity;antibody impairs memory[J].Immunity,2004,21:179-188.
[15]Titulaer MJ,Dalmau J.Antibodies to NMDA receptor,blood-brain barrier disruption and schizophrenia:A theory with unproven links[J].Molecular Psychiatry,2014,19(10):1054.
[16]Mohagheghi M,Eftekharian MM,Taheri M,et al.Determining the IgM and IgG antibodies titer against HSV1,HSV2 and CMV in the serum of schizophrenia patients[J].Hum Antibodies,2018,26(2):87-93.
[17]Kannan G,Crawford JA,Yang C,et al.Anti-NMDA receptor autoantibodies and associated neurobehavioral pathology in mice are dependent on age of first exposure to Toxoplasma gondii[J].Neurobiol Dis,2016,91:307-314.
[18]Miyamoto S,Miyake N,Jarskog LF,et al.Pharmacological treatment of schizophrenia:A critical review of the pharmacology and clinical effects of current and future therapeutic agents[J].Molecular Psychiatry,2012,17(12):1206-1227.
[19]Kantrowitz JT,Woods SW,Petkova EC,et al.D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia:a pilot,double-blind,placebo-controlled,randomised parallel group mechanistic proof-of-concept trial[J].Lancet Psychiatry,2015,2(5):403-412.
[20]Lennox BR,Deakin J,Zandi M,et al.Anti neuronal cell surface antibodies as a cause of schizophrenia[J].Schizophrenia Bulletin,2015,39(Suppl 1):S1-S358.
[2]Wang AK,Miller BJ.Meta-analysis of Cerebrospinal Fluid Cytokine and Tryptophan Catabolite Alterations in Psychiatric Patients:Comparisons Between Schizophrenia,Bipolar Disorder,and Depression[J].Schizophr Bull,2018,44(1):75-83.
[3]Pollak TA,McCormackb R,Peakman M,et al.Prevalence of anti-N-methyl-D-aspartate(NMDA)receptor antibodies in patients with schizophrenia and related psychoses:a systematic review and meta-analysis[J].Psychol Med,2014,44(12):2475-2487.
[4]Benros ME,Pedersen MG,Rasmussen H,et al.A nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis[J].Am J Psychiatry,2014,171(2):218-226.
[5]Moghaddam B,Javitt D.From revolution to evolution:the glutamate hypothesis of schizophrenia and its implication for treatment[J].Neuropsychopharmacology,2012,37:4-15.
[6]Dalmau J,Tüzün E,Wu HY,et al.Paraneoplastic antiN-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma[J].Ann Neurol,2007,61(1):25-36.
[7]Titulaer MJ,McCracken L,Gabilondo I,et al.Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis:An observational cohort study[J].Lancet Neurol,2013,12(2):157-165.
[8]刘美云,谢琰臣,李继梅.抗NMDA受体脑炎[J].中国神经免疫学和神经病学杂志,2010,17(6):449-451.
[9]Hughes EG,Peng X,Gleichman AJ,et al.Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis[J].J Neurosci,2010,30:5866-5875.
[10]Forray C,Buller R.Challenges and opportunities for the development of new antipsychotic drugs[J].Biochem Pharmacol,2017,143:10-24.
[11]Krystal JH,Karper LP,Seibyl JP,et al.Subanesthetic effects of the noncompetitive NMDA antagonis ketamine in humans:psychotomimetic,perceptual,cognitive,and neuroendocrine responses[J].Arch Gen Psychiatry,1994,51:199-214.
[12]陈小红,周凤,刘兴媛,等.抗NMDA受体脑炎患者1例报道及文献学习[J].中国实用神经疾病杂志,2018(8):905-908.
[13]Javitt DC,Zukin SR.Recent advances in the phencyclidine model of schizophrenia[J].Am J Psychiatry,1991,148:1301-1308.
[14]Kiowa C,DeGiorgio LA,Nakaoka T,et al.Cognition and immunity;antibody impairs memory[J].Immunity,2004,21:179-188.
[15]Titulaer MJ,Dalmau J.Antibodies to NMDA receptor,blood-brain barrier disruption and schizophrenia:A theory with unproven links[J].Molecular Psychiatry,2014,19(10):1054.
[16]Mohagheghi M,Eftekharian MM,Taheri M,et al.Determining the IgM and IgG antibodies titer against HSV1,HSV2 and CMV in the serum of schizophrenia patients[J].Hum Antibodies,2018,26(2):87-93.
[17]Kannan G,Crawford JA,Yang C,et al.Anti-NMDA receptor autoantibodies and associated neurobehavioral pathology in mice are dependent on age of first exposure to Toxoplasma gondii[J].Neurobiol Dis,2016,91:307-314.
[18]Miyamoto S,Miyake N,Jarskog LF,et al.Pharmacological treatment of schizophrenia:A critical review of the pharmacology and clinical effects of current and future therapeutic agents[J].Molecular Psychiatry,2012,17(12):1206-1227.
[19]Kantrowitz JT,Woods SW,Petkova EC,et al.D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia:a pilot,double-blind,placebo-controlled,randomised parallel group mechanistic proof-of-concept trial[J].Lancet Psychiatry,2015,2(5):403-412.
[20]Lennox BR,Deakin J,Zandi M,et al.Anti neuronal cell surface antibodies as a cause of schizophrenia[J].Schizophrenia Bulletin,2015,39(Suppl 1):S1-S358.